Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10983622 | 0.85 | MAPT (0.51) | MAPTTDP1KDM4EPOLBLMNA | |
| SCHEMBL700669 | 0.85 | MAPT (0.66) | MAPTTDP1KDM4EPOLBLMNA | |
| SCHEMBL660605 | 0.85 | MAPT (0.55) | MAPTTDP1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL857226 | 0.84 | KDM4E (0.65) | MAPTTDP1KDM4EPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL28473659 | 0.83 | MAPT (0.53) | MAPTTDP1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL2491692 | 0.82 | KDM4E (0.43) | MAPTTDP1KDM4EPOLBLMNA | |
| SCHEMBL1496439 | 0.81 | NNMT (0.46) | MAPTTDP1KDM4EPOLBLMNA | |
| SCHEMBL7847837 | 0.81 | KDM4E (0.49) | MAPTTDP1KDM4EPOLBLMNA | |
| SCHEMBL3421092 | 0.80 | MAPT (0.50) | MAPTTDP1KDM4EPOLBLMNA | |
| SCHEMBL10407306 | 0.80 | TDP1 (0.50) | MAPTTDP1KDM4EPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906530-A1 | PROCESSES FOR THE SYNTHESIS OF 2-AMINO-4,6-DIMETHOXYBENZAMIDE AND OTHER BENZAMIDE COMPOUNDS | Albemarle Corporation (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014062428-A1 | PROCESSES FOR THE SYNTHESIS OF 2-AMINO-4,6-DIMETHOXYBENZAMIDE AND OTHER BENZAMIDE COMPOUNDS | ALBEMARLE CORPORATION (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2013156869-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | WO | disclosed |
| CN-101353328-B | Preparation of 2-chlorin-4-amido-6,7-dimethoxy quinazoline | CHONGQING WORLD HAORUI PHARM CHEM CO LTD | 2010-12-15 | — | — | CN | disclosed |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
| CN-101460490-A | Substituted ring fused azines and their use in cancer therapy | AUCKLAND UNISERVICES LTD (NZ) | 2009-06-17 | — | — | CN | disclosed |
| CN-101353328-A | Preparation of 2-chlorin-4-amido-6,7-dimethoxy quinazoline | CHONGQING WORLD HAORUI PHARM C (CN) | 2009-01-28 | — | — | CN | disclosed |
| CN-1089090-C | Preparation method of 6,7-dimethoxy-2,4-(1H,3H)-quinazoline diketon | SHANYONG MEDICINE UNIV (CN) | 2002-08-14 | — | — | CN | disclosed |
| CN-1150948-A | Preparation method of 6,7-dimethoxy-2,4-(1H,3H)-quinazoline diketon | SHENYANG MEDICINE UNIV (CN) | 1997-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | MAPT 4852/4885TDP1 2178/4885KDM4E 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.